NACC2 and pilocytic astrocytoma: The first NACC2-NTRK2(ex4:ex13) fusion was discovered in pilocytic astrocytoma [9], which is a World Health Organization (WHO) grade 1 tumor exhibiting a 10-year survival rate over 90%.